Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 12/20 | 0.42 |
| ▸ | MERTK | Q12866 | 12/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.41 |
| ▸ | GSK3B | P49841 | 3/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | CCNC | P24863 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL473808 | 0.98 | CHRM1 (0.43) | AXLMERTKCHRM1GSK3BDYRK1A | |
| SCHEMBL473728 | 0.98 | CHRM1 (0.43) | AXLMERTKCHRM1GSK3BDYRK1A | |
| SCHEMBL11907936 | 0.90 | CHRM1 (0.49) | CHRM1GSK3BDYRK1ACHEK1ACHE | |
| SCHEMBL11908023 | 0.89 | CHEK1 (0.40) | CHRM1GSK3BDYRK1ACHEK1ACHE | |
| SCHEMBL473706 | 0.89 | CHRM1 (0.51) | CHRM1GSK3BDYRK1ACHEK1ACHE | |
| SCHEMBL11929499 | 0.88 | CHRM1 (0.43) | AXLMERTKCHRM1GSK3BDYRK1A | |
| SCHEMBL11907420 | 0.88 | CHRM1 (0.43) | AXLMERTKCHRM1GSK3BDYRK1A | |
| SCHEMBL11929500 | 0.88 | CHRM1 (0.42) | AXLMERTKCHRM1GSK3BDYRK1A | |
| SCHEMBL3723670 | 0.88 | CHRM1 (0.42) | AXLMERTKCHRM1GSK3BDYRK1A | |
| SCHEMBL11907671 | 0.87 | CHRM1 (0.41) | CHRM1GSK3BDYRK1ACHEK1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120208809-A1 | 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| EP-2411389-A2 | 9H-PYRROLO[2,3-B: 5,4-C']DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010109084-A2 | 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208809-A1 | 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | NPR3, CCNH, CBR3 | AXL 4295/4885MERTK 3826/4885CHRM1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.